Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gelesis

Explore full profile

Biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients

Boston, United StatesFounded 2006Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2026
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding

About Gelesis

Gelesis is a biotechnology company focused on developing innovative therapies for gastrointestinal (GI) related chronic diseases. The company's proprietary platform features the first and only superabsorbent hydrogel made exclusively from naturally derived building blocks. Gelesis primarily serves adults who are overweight or obese, with a Body Mass Index (BMI) of 25 to 40, by offering products like PLENITY, which aids in weight management when combined with diet and exercise. The company operates in the healthcare and biotechnology market, targeting conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Type 2 diabetes, and Chronic Idiopathic Constipation (CIC). Gelesis generates revenue through the sale of its hydrogel-based therapies and continues to expand its pipeline of potential treatments for various GI-related conditions.

Source: Dealroom company data

At a glance

Founded
2006
Headquarters
Boston, United States
Listing
Public via SPAC 2021
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Latest news

Press, funding announcements and product moves mentioning Gelesis.

See all news

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • BIRD Foundation

Series A3 investors entered at this stage

Series B and later9 investors entered at this stage

  • Cormorant Asset Management
  • Invesco
  • Vitruvian Partners
  • China Medical System Holdings
  • PV Capital Management
  • Pacific investment Management
  • Kennedy Lewis Investment Management
  • Capstar Special Purpose Acquisition Corp
  • Theras

Talent

Book a demo to see the people
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇮🇹 Italy87.9%
🇺🇸 United States6.1%
🇬🇧 United Kingdom3%
🇮🇱 Israel3%
4 countries shown
Web traffic by country
2.4K monthly visits
across markets
🇺🇸 United States54.2%
🇮🇹 Italy50%
Top 2 markets shown

Patents

Estimated portfolio value
$47M

18 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Gelesis on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gelesis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles